Brief: Cidara Shares Phase 2B CD388 Data, H5N1 Preclinical Results At ISRV’s 8th AVG & 3rd IMRP 2025 Meeting
17/09/2025 13:36
Sept 17 (Reuters) - Cidara Therapeutics Inc CDTX.O: CIDARA THERAPEUTICS PRESENTS DATA ON CD388 FROM ITS PHASE 2B NAVIGATE TRIAL AND PRECLINICAL STUDIES AGAINST H5N1 AT ISRV’S 8TH AVERAGE AND 3RD IMRP 2025 MEETING Source text: ID:nGNX3GF8ZQ Further company coverage: CDTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cidara Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merck Seeks Up To $8 Billion In Us Bond Sale Tied To Cidara Deal - Bloomberg News
Merck rises after Wells Fargo upgrades stock to 'overweight'
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade